• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us

Establishment of Immune Biobank for Vaccine Immunogenicity Prediction Using In Vitro and In Silico Methods Against Porcine Reproductive and Respiratory Syndrome Virus

by Elena Iemma | Oct 14, 2025

Poster: T cell Epitope Content Comparison (EpiCC) of swine H1 influenza A virus hemagglutinin to identify best vaccine match

by Elena Iemma | Jan 8, 2024

Poster: iVAX for antigen discovery, vaccine design, diagnostics, and epidemiology

Poster: iVAX for antigen discovery, vaccine design, diagnostics, and epidemiology

by Elena Iemma | Sep 22, 2023

Comparison of Predicted T cell Epitopes in Porcine Circovirus Type 2 Isolates from 2017 to 2021 and Selected Vaccines (EpiCC Analysis) Confirms the Global Relevance of a Bivalent Vaccine Approach

by Elena Iemma | May 25, 2023

Comparison of Predicted T cell Epitopes in Porcine Circovirus Type 2 Isolates from 2017 to 2021 and Selected Vaccines (EpiCC Analysis) Confirms the Global Relevance of a Bivalent Vaccine Approach
H1N1 G4 swine influenza T cell epitope analysis in swine and human vaccines and circulating strains uncovers potential risk to swine and humans

H1N1 G4 swine influenza T cell epitope analysis in swine and human vaccines and circulating strains uncovers potential risk to swine and humans

by Elena Iemma | Oct 26, 2022

« Older Entries

Recent Posts

  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic
  • EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide
  • Doing Well and Giving Back in December
  • The Power of Tregs: From Sakaguchi’s Nobel Discovery to EpiVax Innovation
  • The Tregs as Medicine Symposium | Advances in Tolerance Research

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.